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and Chemotherapy
the therapeutic window in which these agents could be
used. At that time, drug resistance was thought to arise
from molecular changes inhibiting the drug-target inter-
action (Figure 1). Indeed, the discovery of drug pumps
such as P-glycoprotein and intracellular detoxifiers such
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drug-induced insult also play an important role. Chemo-
therapeutic agents can induce a series of cellular re-
sponses that impact on tumor cell proliferation and sur-Defects in apoptosis underpin both tumorigenesis and
vival (Lowe and Lin, 2000) (Figure 1). Perhaps the bestdrug resistance, and because of these defects chemo-
studied of these cellular responses is apoptosis, a physi-therapy often fails. Understanding the molecular events
ological cell death program that controls normal cellthat contribute to drug-induced apoptosis, and how
numbers during development and disease. We now un-tumors evade apoptotic death, provides a paradigm
derstand many of the molecular events necessary forto explain the relationship between cancer genetics
activation, amplification and execution of the apoptoticand treatment sensitivity and should enable a more ratio-
process, and it is evident that diverse drugs can killnal approach to anticancer drug design and therapy.
tumor cells by activating common apoptotic pathways.
Thus, single mutations that disable apoptosis can pro-
duce multidrug resistance.Introduction
The realization that apoptosis contributes to the anti-Chemotherapy for the treatment of cancer was intro-
tumor activity of many chemotherapeutic drugs has al-duced into the clinic more than fifty years ago. Although
lowed us to rethink how intrinsic drug resistance maythis form of therapy has been successful for the treat-
arise. For a tumor cell to propagate, it must survivement of some tumors such as testicular cancer and
drastic structural and/or metabolic alterations, as well ascertain leukemias, its success for the treatment of com-
an extremely stressful microenvironment (i.e., hypoxicmon epithelial tumors of the breast, colon, and lung has
conditions and nutrient deprivation). It also must evadebeen less than spectacular. Ideally, chemotherapeutic
the host antitumor immune response. As discusseddrugs should specifically target only neoplastic cells
herein, altered expression or mutation of genes encod-and should decrease tumor burden by inducing cyto-
ing key apoptotic proteins can provide cancer cells withtoxic and/or cytostatic effects with minimal “collateral
both an intrinsic survival advantage and inherent resis-damage” to normal cells. In reality, the effectiveness of
tance to chemotherapeutic drugs. This “double whammy”chemotherapy has suffered from a range of confounding
results in the growth and expansion of neoplastic cellsfactors including systemic toxicity due to a lack of speci-
in the first instance and may thwart subsequent therapy.ficity, rapid drug metabolism, and both intrinsic and
The overall contribution of apoptotic defects to clini-acquired drug resistance. The problem of multidrug re-
cal multidrug resistance remains under debate (Brown
sistance has been the least understood, and most un-
and Wouters, 1999). However, accepting that there is a
predictable factor affecting chemotherapy. Given the
causal relationship between apoptosis and drug-induced
adaptability of tumor cells, it seems likely that drug resis- cytotoxicity has several implications that we will address
tance will continue to be an important clinical problem, in this review. First, the similarity between physiological
even in the age of targeted therapeutics and tailored and drug-induced apoptotic programs establishes a
treatment regimes. clear link between tumor development and intrinsic re-
Why are tumors often inherently resistant to chemo- sistance to anticancer treatment, and thus provides a
therapeutic drugs or become resistant after an initial round biological basis for how tumor genotype can determine
of treatment? Our understanding of drug resistance has treatment outcome. Second, the fact that defects in
evolved over time due to a clearer understanding of how apoptosis can promote drug resistance downstream of
conventional drugs actually kill tumor cells. Initially, the the drug-target interaction raises the possibility that ge-
development of chemotherapeutic agents was based notoxic agents may induce further genetic mutations
on the observation that tumor cells proliferate faster owing to “damage without death.” Third, the efficiency
than normal cells. Thus, drugs that interfered with DNA with which apoptosis can eliminate tumor cells when
replication or cellular metabolism were chosen. Predict- engaged indirectly by conventional agents provides a
ably, these agents also affected rapidly dividing normal strong rationale for strategies to target the process more
cells of the bone marrow and gut, thereby reducing directly. Finally, the sensitivity of normal cells to drug-
induced apoptosis may explain many of the toxic side
effects of conventional chemotherapy and suggests3 Correspondence: r.johnstone@pmci.unimelb.edu.au [R.W.J.]; lowe@
cshl.org [S.W.L.] strategies to minimize them. It follows that a detailed
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Figure 1. Mechanisms of Drug Action
Addition of chemotherapeutic drugs to tumor cells results in interaction between the drug and intracellular targets, and induction of the
primary effect. Classical drug resistance proteins such as drug efflux pumps can inhibit the primary effect by affecting drug-target interactions.
Depending on the severity of the initial insult, drug-induced damage may result in catastrophic death or initiate a series of secondary effects
mediated by various stress signaling pathways leading to cell death or cell cycle arrest. Consequently, mutations in these downstream events
can produce multidrug resistance.
understanding of how anticancer agents induce cell way can be regulated by c-FLIP, which inhibits upstream
death, and how defects in death pathways promote re- activator caspases, and inhibitor of apoptosis proteins
sistance, will revolutionize the way chemotherapeutic (IAPs), which affect both activator and effector cas-
drugs are designed and used, moving from “trial and pases. The intrinsic pathway requires disruption of the
error” to a more rational strategy that may be tailored mitochondrial membrane and the release of mitochon-
to each cancer patient. drial proteins including Smac/DIABLO, HtRA2, and cyto-
chrome c. Cytochrome c functions with Apaf-1 to induce
activation of caspase-9, thereby initiating the apoptoticDisabling Apoptosis: An Important Process
caspase cascade, while Smac/DIABLO and HtrA2 bindin Tumor Formation
to and antagonize IAPs (Wang, 2001; Suzuki et al., 2001).To appreciate how alterations in apoptotic pathways
Mitochondrial membrane permeabilization is regu-impinge on drug action, it is necessary for us to first
lated by the opposing actions of pro- and antiapoptoticoutline their role in tumorigenesis. Tumorigenesis is a
Bcl-2 family members. Multidomain proapoptotic Bcl-2multistep process in which mutations in key cellular
proteins (e.g., Bak and Bax) can be activated directlygenes produce a series of acquired capabilities that
following interaction with the BH3-only Bcl-2 proteinallow the developing cancer cell to grow unchecked in
Bid. Alternatively, binding of other BH3-only proteinsthe absence of growth-stimulating signals, while over-
(e.g., Noxa, Puma, Bad, and Bim) to antiapoptotic Bcl-2coming growth-inhibitory signals and host immune re-
proteins (e.g., Bcl-2 and Bcl-XL) results in activation ofsponses. They also allow the tumor to replicate indefi-
Bax and Bak (Adams and Cory, 1998; Huang and Stras-nitely, maintain an oxygen and nutrient supply, and
ser, 2000). Whether Bcl-2 proteins control mitochondrialinvade adjacent and distant tissues. Importantly, the
membrane permeability by directly forming pores in theability of cells to evade apoptosis is also an essential
outer membrane, and/or by regulating the opening and“hallmark of cancer” (Hanahan and Weinberg, 2000).
closing of the permeability transition pore remains theComponents of Apoptotic Pathways
topic of much debate (Martinou and Green, 2001). TheApoptosis is defined by distinct morphological and bio-
net effect however, is the regulated release of proapo-chemical changes mediated by a family of cysteine as-
ptotic factors from the mitochondria, induction of down-pases (caspases), which are expressed as inactive zy-
stream caspases, and potential loss of mitochondrialmogens and are proteolytically processed to an active
function (Figure 2).state following an apoptotic stimulus. Two separable
There is considerable cross-talk between the extrinsicpathways leading to caspase activation have been char-
and intrinsic pathways. For example, caspase-8 canacterized (Green, 2000; Wang, 2001) (Figure 2). The ex-
proteolytically activate Bid, which can then facilitate cy-trinsic pathway is initiated by ligation of transmembrane
tochrome c release (Green, 2000). This apparently ampli-death receptors (CD95, TNF receptor, and TRAIL recep-
fies the apoptotic signal following death receptor activa-tor) to activate membrane-proximal (activator) caspases
tion, and different cell types may be more reliant on this(caspase-8 and -10), which in turn cleave and activate
effector caspases such as caspase-3 and -7. This path- amplification pathway than others (Fulda et al., 2001).
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Figure 2. The Integrated Apoptotic Pathways
A schematic diagram showing some of the
known components of the intrinsic and death
receptor apoptotic programs that may modu-
late tumor development and therapy. An as-
terisk denotes components that are fre-
quently mutated or aberrantly expressed in
human cancers. Components in red inhibit
apoptosis while those in green promote apo-
ptosis. Abbreviations used: casp, caspase;
cyt, cytochrome.
Conversely, activators of the intrinsic pathway can sen- eral prosurvival kinases including Akt, p90S6K, p70S6K,
and PKA, inhibits its interaction with antiapoptotic Bcl-2sitize the cell to extrinsic death ligands (see below).
Regulation of the Intrinsic Apoptotic Pathway proteins, and induces sequestration of Bad away from
the mitochondria following binding of 14-3-3 adaptor“Intrinsic stresses” such as oncoproteins, direct DNA
damage, hypoxia, and survival factor deprivation, can proteins (Bonni et al., 1999; Harada et al., 2001; Wang,
2001). Moreover, Bcl-2 can be directly phosphorylatedactivate the intrinsic apoptotic pathway. As a sensor of
cellular stress, p53 is a critical initiator of this pathway by MAP kinases and dephosphorylated by the PP2A
tumor suppressor, leading to changes in its activity (Bla-(Lowe and Lin, 2000) (Figure 2). For example, proteins
that sense DNA damage, such as ATM and Chk2, phos- gosklonny, 2001).
Tumors Dysregulate the Intrinsic Pathwayphorylate and stabilize p53 directly, and inhibit MDM2-
mediated ubiquitination of p53 (Khanna and Jackson, Disruption of the intrinsic apoptotic pathway is ex-
tremely common in cancer cells (Table 1). Indeed, the2001). Mitogenic oncogenes can also activate p53 through
a mechanism that is distinct from DNA damage, and can p53 tumor suppressor gene is the most frequently mu-
tated gene in human tumors, and loss of p53 functioninvolve p19ARF, the alternative reading frame product of
the INK4a/ARF tumor suppressor locus. p19ARF, in turn, can both disable apoptosis and accelerate tumor devel-
opment in transgenic mice (Attardi and Jacks, 1999;binds and inactivates Mdm2, leading to p53 activation
(Lowe and Lin, 2000; Sherr and Weber, 2000). Ryan et al., 2001). Moreover, functional mutations or
altered expression of p53 downstream effectors (PTEN,p53 can initiate apoptosis by transcriptionally activat-
ing proapoptotic Bcl-2 family members (e.g., Bax, Bak, Bax, Bak, and Apaf-1), or upstream regulators (ATM,
Chk2, Mdm 2, and p19ARF), occur in human tumors (TablePUMA, and Noxa) and repressing antiapoptotic Bcl-2
proteins (Bcl-2, Bcl-XL) and IAPs (survivin) (Bartke et al., 1). As a result, the presence of wild-type p53 does not
necessarily indicate that the pathway is intact, thus com-2001; Hoffman et al., 2001; Ryan et al., 2001; Wu et al.,
2001). However, p53 can also transactivate other genes plicating efforts to correlate p53 gene integrity with a
functional p53 pathway (Schmitt et al., 1999).that may contribute to apoptosis including PTEN,
Apaf-1, PERP, p53AIP1, and genes that lead to in- Given the importance of Bcl-2 family members in regu-
lating the intrinsic apoptotic pathway, it is not surprisingcreases in reactive oxygen species (ROS) (Hwang et al.,
2001; Moroni et al., 2001; Ryan et al., 2001; Stambolic et that these genes are altered in tumor samples (Table 1).
In fact, Bcl-2 was first identified based on its transloca-al., 2001). In addition, p53 can transcriptionally activate
both CD95 and TRAIL receptor 2 (TRAIL-R2/DR5), tion in follicular lymphoma, and is overexpressed in a
variety of cancers (Reed, 1999). Moreover, Bcl-2 overex-thereby sensitizing cells to death-receptor-mediated
apoptosis (Herr and Debatin, 2001; Ryan et al., 2001). pression can accelerate tumorigenesis in transgenic
mice (Adams et al. 1999). Conversely, proapoptoticp53 may also have transcription-independent activities
that potentiate cell death once the transcription-depen- Bcl-2 proteins are inactivated in certain cancers and
disruption of these genes also promotes tumorigenesisdent functions initiate the process (Ryan et al., 2001).
Therefore, it appears that p53 can function as a “master in mice (Table 1). In addition, mutations or altered ex-
pression of upstream regulators of Bcl-2 proteins areregulator” of the apoptotic program, capable of coordi-
nating the process at multiple levels via several mecha- associated with cancer. For example, the Bad-kinase
Akt, is positively regulated by various oncoproteins, andnisms. Still, p53 is not the only activator of the intrinsic
apoptotic pathway. Some studies suggest that a related negatively regulated by the PTEN tumor suppressor
(Datta et al., 1999). Amplified Akt and mutated PTENfamily member, p73, might substitute for p53 in certain
circumstances (Yang and McKeon, 2000). Undoubtedly, have been found with high frequency in a variety of solid
cancers, indicating the importance of this pathway inadditional p53-independent activities are also important.
In addition to transcriptional regulation by p53, the regulating tumorigenesis (Table 1).
Inhibition of Postmitochondrial Death Processesactivities of Bcl-2 proteins can be modulated by post-
translational modifications such as phosphorylation While mutations in cancer cells often target regulators
of the intrinsic apoptotic pathway such as p53 and the(Figure 2). For example, phosphorylation of Bad by sev-
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Table 1. Summary of the Roles of Apoptotic Initiators, Regulators or Executioners in Tumorigenesis, Apoptosis, and Drug Resistance
Protein Role in tumorigenesis, apoptosis and drug resistance References
Tumor
Suppressor
p53 Mutated or altered expression in many cancers. Initiates the intrinsic apoptotic (Vogelstein et al., 2000)
pathway. p53/ cells are resistant to drug induced apoptosis.
p19ARF Mutated or altered expression in many cancers. Blocks MDM2 inhibition of p53. (Sherr and Weber, 2000)
Enhances drug-induced apoptosis by p53.
ATM Mutated in ataxia-talangiectasia syndrome. Senses DNA double strand breaks (Khanna and Jackson, 2001)
and stabilizes p53. Deficiencies increase risk of developing haematological
malignancies and breast cancer.
Chk2 Mutated in Li-Fraumeni syndrome. Senses DNA double strand breaks and (Khanna and Jackson, 2001)
phosphorylates and stabilizes p53.
Rb Mutated in some cancers, and functionally disrupted in many cancers. Inhibits (Harbour and Dean, 2000)
E2F-medidated transcription. Loss of Rb function induces p53-dependent and
independent apoptosis.
Bax Mutated or decreased expression in some tumors. Mediates mitochondrial (Rampino et al., 1997)
membrane damage. Sufficient but not necessary for drug-induced apoptosis.
Bak Mutated or decreased expression in some tumors. Mediates mitochondrial (Kondo et al., 2000)
membrane damage. Sufficient but not necessary for drug-induced apoptosis.
PTEN Mutated or altered expression in cancers. Regulates Akt activation and (Di Cristofano and Pandolfi, 2000)
subsequent phosphorylation of Bad. Loss of PTEN results in resistance
to many apoptotic stimuli.
Apaf-1 Mutated and transcriptionally silenced in melanoma and leukemia cell lines. (Soengas et al., 2001)
Necessary for activation of caspase-9 following cytochrome c release.
Apaf-1/ cells are chemoresistant.
CD-95/Fas Mutated and down-regulated in lymphoid and solid tumors. Initiates the extrinsic (Muschen et al., 2000)
apoptotic pathway. Loss of function is associated with resistance to
drug-induced cell death.
TRAIL-R1/R2 Mutated in metastatic breast cancers. Initiate the extrinsic apoptotic pathway. (Shin et al., 2001)
Mutations lead to suppression of death receptor-mediated apoptosis.
Caspase-8 Gene silenced in neuroblastomas. Activates both extrinsic and intrinsic apoptotic (Teitz et al., 2000)
pathways. Silencing results in resistance to drug-induced apoptosis.
Oncogene
Bcl-2 Frequently overexpressed in many tumors. Antagonises Bax and/or Bak and (Reed, 1999)
inhibits mitochondrial membrane disruption. Inhibits drug-induced apoptosis.
MDM2 Overexpressed in some tumors. Negative regulator of p53. Inhibits drug-induced (Sherr and Weber, 2000)
p53 activation.
IAPs Frequently overexpressed in cancer. Down regulation of XIAP induces apoptosis (Deveraux and Reed, 1999)
in chemoresistant tumors.
NF-B Deregulated activity in many cancers. Transcriptionally activates expression of (Baldwin, 2001)
anti-apoptotic members of the Bcl-2 and IAP families. Can inhibit both the
extrinsic and intrinsic death pathways and induce drug-resistance.
Myc Deregulated expression in many cancers. Induces proliferation in the presence (Evan and Vousden, 2001)
of survival factors, such as Bcl-2, and apoptosis in the absence of survival
factors. Can sensitise cells to drug-induced apoptosis.
Akt Frequently amplified in solid tumors. Phosphorylates Bad. Hyperactivation (Datta et al., 1999)
induces resistance to a range of apoptotic stimuli including drugs.
PI3K Overexpressed or deregulated in some cancers. Responsible for activation of (Roymans and Slegers, 2001)
Akt and downstream phosphorylation of Bad. Inhibition of PI3K enhances
chemotherapeutic drug-induced apoptosis.
Ras Mutated or deregulated in many cancers. Activates PI3K and downstream (el-Deiry, 1997)
pathways. Induces proliferation and inhibits c-myc and drug-induced
apoptosis.
FLIP Overexpressed in some cancers. Prevents activation of caspase-8 and apoptosis (Tepper and Seldin, 1999)
induced by some chemotherapeutic drugs.
Bcl-2-related proteins, alterations that disrupt apoptosis dancy in the downstream pathway, or the difficulty in
maintaining cell viability following damage to the mito-downstream of the mitochondria have been reported
(Table 1). For example, silencing of Apaf-1 occurs in chondria. Consistent with the latter possibility, cell death
can sometimes proceed in the presence of caspasemetastatic melanoma, and overexpression of IAPs and
heat shock proteins (Hsp), which can inhibit caspase-9 inhibitors (Herr and Debatin, 2001).
Tumor Cells Evade Death-Receptor-Inducedactivation, is commonly observed in human tumors (De-
veraux and Reed, 1999; Soengas et al., 2001; Beere and Apoptosis
Tumorigenic disruptions in the death-receptor pathwayGreen, 2001). This implies that downstream defects in
apoptosis contribute to tumorigenesis. Nevertheless, occur less frequently than the intrinsic pathway. Never-
theless, tumor cells are often resistant to death-recep-postmitochondrial mutations appear less frequently
than those targeting upstream components of the apo- tor-mediated apoptosis, and mutations in CD95, TRAIL
receptors, and downstream signaling pathways do oc-ptotic program. This could represent greater redun-
Review
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cur in cancer (Table 1). Autoimmune lymphoproliferative 2001) and, in some settings, p53 loss can enhance drug-
induced cell death (Bunz et al., 1999). Still, loss of p53syndrome (ALPS) is caused by germline mutations in
function correlates with multidrug resistance in manyCD95 resulting in inappropriate survival of activated
tumor types (Wallace-Brodeur and Lowe, 1999).T lymphocytes. ALPS patients have an increased inci-
Mutations or altered expression of Bcl-2-related pro-dence of lymphoma, possibly due to the expanded pop-
teins can drastically alter drug sensitivity in experimentalulation of apoptosis-resistant T cells which can sustain
models (Reed, 1999; Schmitt et al., 2000; Wei et al., 2001;further transforming mutations (Straus et al., 2001). In
Zhang et al., 2000), and are associated with multidrugsolid tumors and non-T cell leukemias, tumor surveil-
resistance in human cancers (Reed, 1999). Althoughlance and immune escape may also be important. While
Bcl-2 does not promote long-term proliferation followingcytotoxic lymphocytes predominantly kill tumor cells via
drug treatment in all settings (Brown and Wouters, 1999),the granule exocytosis pathway (Trapani et al., 2000),
evidence now suggests that this reflects limitations ofCD95L and TRAIL are also utilized (Rosen et al., 2000;
certain in vitro assays. For example, in primary lympho-Takeda et al., 2001). Thus, inactivation of the death re-
mas derived from c-myc transgenic mice, overexpres-ceptor pathway could allow escape from immune re-
sion of Bcl-2 significantly inhibits drug-induced deathsponses and provide a survival advantage to developing
in short term assays, but does not enhance clonogenictumor cells. In fact, loss of CD95L or TRAIL function can
potential (Schmitt et al., 2000). Nevertheless, Bcl-2-over-promote tumor growth and metastasis (Rosen et al.,
expressing lymphomas are highly drug resistant in vivo.2000; Takeda et al., 2001)
Similarly, Bcl-XL-overexpressing breast carcinoma lines,Thus, apoptosis is regulated at many levels, including
which lose clonogenic potential following exposure tothe initiation, transduction, amplification, and execution
chemotherapeutic drugs in vitro, are resistant to drug-stages, and mutations that disrupt each of these stages
induced cell death in vivo (Liu et al., 1999).have been detected in tumor cells. Because mutations
How can the discrepancy between clonogenic assaysin cancers necessarily produce a selective advantage
in culture and tumor responses in vivo be reconciled?to emerging tumor cells, the identification of mutated
As clonogenic assays not only represent survival of acomponents and their frequency of mutation highlight
cell but also cell proliferation, Bcl-2 may not block drug-critical regulatory points in survival and proliferative pro-
induced cytostasis, which would be indistinguishablecesses. The fact that apoptosis is disabled at distinct
from cell death in this assay. Indeed, IL-7 is a growthstages in different tumor types suggests that its critical
stimulatory cytokine that can increase the clonogeniccontrol points are probably context dependent. As dis-
potential of Bcl-2-overexpressing lymphomas (Schmittcussed below, this variability may contribute to the het-
et al., 2000), and a combination of microenvironmentalerogeneity of treatment responses in human tumors.
survival signals cooperates with Bcl-XL to promote clo-Moreover, the identification of these control points sin-
nogenic survival following drug treatment in B lym-gle out distinct “sites of attack” for targeting by novel
phoma cells (Walker et al., 1997). Therefore, the microen-chemotherapeutic drugs.
vironment can have a substantial impact on the ability
of Bcl-2 to promote long-term survival. Moreover, evenCancer Therapy and Apoptosis
when anticancer agents induce cytostasis in the pres-
Since most cancer drugs were identified using empirical
ence of an apoptotic block, the increase in tumor burden
screens, the molecular events responsible for their anti-
may provide a window of opportunity for survival of a
tumor effect were poorly understood. Over the last de- more malignant variant with a defect in drug-induced
cade, our understanding of cellular damage responses cytostasis.
and physiological cell death mechanisms has improved, Postmitochondrial Events and Drug Action
leading in turn to new insights into drug-induced cell Although the contribution of postmitochondrial events
death. Drugs of differing structure and specificity induce to drug action are less well defined, defects at this level
the characteristic morphological changes associated can also promote drug resistance. For example, epige-
with apoptosis, and it is now believed that apoptotic netic inactivation of Apaf-1 in malignant melanoma, and
pathways contribute to the cytotoxic action of most increases in IAP and Hsp expression in various tumors,
chemotherapeutic drugs (Lowe and Lin, 2000). Collec- correlates with drug resistance (Creagh et al., 2000; Dev-
tively, these observations indicate that cells can inter- eraux and Reed, 1999; Soengas et al., 2001). Interest-
pret a drug-induced insult in the same way that a physio- ingly, melanoma cells with reduced Apaf-1 expression
logical insult, such as hypoxia or growth factor deprivation, efficiently activate p53 in response to a chemotherapeu-
is interpreted. Since the efficiency of apoptosis depends tic drug, but fail to activate caspase-9 and initiate an apo-
on the integrity of an elaborate molecular network, the ptotic response. Importantly, reintroduction of Apaf-1 can
killing of tumor cells by anticancer agents may be re- reactivate caspase-9 and restore drug-induced apopto-
markably indirect. sis. In addition, loss of Apaf-1 expression or activity in
Anticancer Drugs Activate the Intrinsic human leukemia and ovarian carcinoma cell lines corre-
Apoptotic Pathway lates with a decrease in drug-induced apoptosis, and
Mutations in p53 or in the p53 pathway can produce multi- these cells can be resensitized to drug following trans-
drug resistance in vitro and in vivo, and reintroduction of fection of Apaf-1 (Jia et al., 2001; Wolf et al., 2001).
wild-type p53 into p53 null tumor cells can re-establish These findings suggest that release of cytochrome c
chemosensitivity (Wallace-Brodeur and Lowe, 1999). from the mitochondria may not always be the “point of
However, p53 status is not a universal predictor of treat- no return” with respect to cell survival following drug
ment response, in part because not all drugs absolutely treatment. Although mitochondrial membrane damage
triggers the caspase cascade, it also releases other pro-require p53 for their apoptotic function (Herr and Debatin,
Cell
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apoptotic factors and disrupts essential metabolic pro- while others require only the mitochondrial pathway
cesses such as ATP production by oxidative phosphory- (Fulda et al., 2001). Given the ability of p53 to transacti-
lation (Wang, 2001). Nevertheless, in some settings, cells vate CD95 and DR5, it is also possible that this contrib-
with apoptotic defects apparently downstream of the utes to drug-induced cell death in microenvironments
mitochondria survive despite perturbation of the mito- where there is substantial ligand present (Herr and De-
chondrial membrane. For example, mice lacking apaf-1, batin, 2001; Ryan et al., 2001).
caspase-9, or caspase-3 display massive cell accumula- In some cases, the very stimulus that induces apopto-
tion in the developing nervous system (Los et al., 1999), sis also initiates an antagonistic antiapoptotic program.
and loss of apaf-1 rescues some, but not all, of the For example, TNF engagement with its receptor can
aberrant apoptosis observed in Rb-deficient embryos simultaneously signal apoptosis and upregulate the pro-
(Guo et al., 2001). Similarly, transformed fibroblasts from survival transcription factor NF-B, and its ability to in-
apaf-1 or caspase-9 knockout mice are resistant to di- duce cell death may depend on the balance between
verse apoptotic stimuli, including chemotherapeutic drugs these two processes (Baldwin, 2001). This presumably
(Los et al., 1999; Soengas et al., 1999). However, this allows life and death decisions to be more tightly regu-
is not universally true, since apaf-1/ and caspase-9/ lated. Strikingly, certain chemotherapeutic drugs also
lymphoid and myeloid cells still undergo developmen- activate the NF-B pathway and inhibition of NF-B sen-
tally programmed cell death in vivo, and are sensitive sitizes cells to drug-mediated death (Baldwin, 2001).
to cytokine withdrawal and drug-induced apoptosis in This “inducible drug resistance” observed experimen-
culture (V. Marsden, J.M. Adams and A. Strasser, per- tally implies that many of the agents used to treat cancer
sonal communication). Moreover, fibroblasts from these initiate a protective response that thwarts their intended
mice are not as resistant to Bid-induced apoptosis as action. While the generality of this effect is not certain
those lacking Bax and Bak, or overexpressing Bcl-2 (Ryan et al., 2000), these data provide novel insight into
(Cheng et al., 2001). the molecular mechanisms of drug resistance and have
The ability of some tumor cells with postmitochondrial therapeutic implications.
defects to survive chemotherapy presents a conun- Although drug resistance may occur upstream or
drum. Even in the absence of downstream caspase downstream of the drug-target interaction, these two
activation, damage to the mitochondrial membrane and mechanisms are not mutually exclusive. In addition to
release of cytochrome c still disrupts the electron trans- actively effluxing chemotherapeutic drugs, the multi-
port chain and enhances ROS production. How might drug resistance protein, P-gp can also protect cells
the cell tolerate this damage? Following initiation of the against apoptosis mediated by the death receptor path-
intrinsic apoptotic pathway and in the absence of cas- way, UV-irradiation, and serum starvation (Johnstone et
pase activation, mitochondria can restore transmem- al., 2000). Similarly, the high levels of anti-oxidants often
brane potential and maintain ATP production (Water- observed in drug-resistant tumors are thought to pro-
house et al., 2001). This can occur following the mote resistance upstream of the intracellular target
relocalization of cytoplasmic cytochrome c back into (Volm, 1998), but may act downstream as well. ROS
the mitochondria, a truly remarkable feat that infers that contribute to p53-mediated apoptosis following 5-fluo-
mitochondrial structure is preserved, or can rapidly re- rouracil (5-FU) treatment of colon carcinoma cells, and
cover, after cytochrome c release. Thus, in a situation genetic manipulation to reduce ROS, or the addition of
where Apaf-1 or downstream caspases are inactivated, exogenous antioxidants, can dramatically reduce drug-
the mitochondrial membrane damage that accompanies induced apoptosis (Hwang et al., 2001). The potential
apoptosis may not always result in a “lethal hit” to the for single drug resistance mechanisms to inhibit drug
cell. Interestingly, the capacity of some tumor cells to action at multiple levels illustrates the complexity of the
tolerate mitochondrial dysfunction may be because they problem.
frequently express elevated levels of antioxidants (Volm, In summary, there is growing evidence that disruption
1998), and are often growing in glycolytic conditions and of apoptotic pathways contribute to drug resistance,
therefore rely less on oxidative phosphorylation than with lesions upstream of mitochondrial damage produc-
normal cells (Dang and Semenza, 1999). Thus, the long- ing the greatest effect. However, it is important to re-
term survival of cells containing postmitochondrial de-
member that other drug-induced effects such as cyto-
fects in apoptosis probably depends on several factors
stasis and mitotic catastrophe can augment apoptosis
including the intensity of the stimulus, the cellular con-
to help reduce the tumor burden. These additional ef-text, and the physiological microenvironment.
fects may be inhibited by either the same mechanismsOther Resistance Mechanisms
that impact on drug-induced apoptosis (e.g., overex-The contribution of the death receptor pathway in che-
pression of P-glycoprotein), or by other resistancemotherapeutic drug-induced cell death is controversial
mechanisms occurring downstream of the drug-target(Herr and Debatin, 2001). Treatment of tumor cells with
interaction (Figure 1). Although the relative contributiondrugs can induce CD95 and TRAIL receptors, and down-
of each resistance mechanism to clinical multidrug re-regulate c-FLIP and the IAPs (Asselin et al., 2001; Chat-
sistance is not yet known, it is likely to depend on theterjee et al., 2001; Herr and Debatin, 2001). However,
specific activity of the chemotherapeutic drug, as well asexperiments using cells derived from mice with func-
the tissue origin and genetic background of the tumor.tional mutations in the death receptor pathway (i.e.,
FADD and caspase-8 knockout) indicate that this path-
Apoptosis Links Cancer Geneticsway is dispensable for the cytotoxic action of chemo-
and Cancer Therapytherapeutic agents (Los et al., 1999). It has been argued
Our discussion of apoptosis during tumor developmentthat certain cell types require both the death receptor
and mitochondrial pathways for drug-induced death, and following drug treatment reveals that these pro-
Review
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cesses are remarkably similar. Thus, the very genetic rectly damage DNA. Whereas upstream drug resistance
alterations that induce tumorigenesis can also mediate mechanisms such as P-gp overexpression prevent
intrinsic resistance to both physiological (growth factor drug-induced damage, downstream resistance mecha-
withdrawal and hypoxia) and nonphysiological death nisms do not (Figure 1). Hence, inhibition of apoptosis in
stimuli (drugs). As a result, tumors that have never been drug resistant tumors not only affects the death-inducing
challenged with drug can be inherently resistant to con- activities of the drug, but also allows for the possibility
ventional chemotherapeutic agents. Put simply, these of cells acquiring additional mutations following DNA
observations imply that tumor genotype is the most im- damage. In principle, these mutagenized cells could be-
portant parameter underpinning successful chemother- come more malignant and even less sensitive to subse-
apy using current drugs and regimes. This concept has quent therapies, such that treatment of highly resistant
enormous implications for the future of cancer diagnosis tumors containing antiapoptotic lesions may be doing
and treatment, for it suggests that more rational ap- more harm than good.
proaches to chemotherapy will require both an intimate At present there is no definitive proof that treatment
knowledge of the genetic lesions that give rise to tumor of tumors harboring apoptotic lesions is deleterious.
development, as well as a detailed understanding of the However, there is no doubt that the anticancer agents
molecular basis of drug action. can be mutagenic and this property can have clinical
The principal described above couples the disruption ramifications. For example, many cancer patients en-
of apoptosis during tumor development with intrinsic drug counter the problem of therapy-related leukemia, in
resistance. The best demonstration of this is in E-myc
which new primary tumors arise following the treatment
transgenic mice crossed with mice containing only one
of hematological and solid tumors with alkylating agentsfunctional INK4a/ARF (INK4a/ARF/) or p53 (p53/) al-
and topoisomerase inhibitors (Leone et al., 1999). Theselele (Schmitt et al., 1999). The onset of E-myc tumors
leukemias have relatively short latency times, indicatingin INK4a/ARF/ or p53/ mice is greatly accelerated
that they probably arise from premalignant cells, andrelative to control E-myc animals, and the resulting
are associated with an increase in mutation frequency.tumors typically lose the wild-type INK4a/ARF or p53
It seems likely that these agents would be at least asallele. This indicates a strong selective pressure to dis-
mutagenic to the primary tumors, perhaps producing aengage the p53 pathway during lymphoma develop-
more advanced malignancy. Consistent with this possi-ment. The INK4a/ARF null and p53 null tumors are highly
bility, median survival times for leukemias and certaininvasive and less prone to spontaneous apoptosis. Fur-
solid tumors following relapse are often shorter whenthermore, they are more chemoresistant in vitro and in
compared to newly diagnosed patients, and relapsedvivo compared to E-myc tumors alone. These experi-
cancers infrequently achieve long-term remission withments demonstrate that drug resistance does not only
subsequent chemotherapy (Ihde et al., 1997).occur in response to drug challenge, but can be a by-
Studies that have examined the relationship betweenproduct of the process that produces accelerated and
p53 and mutation frequency following DNA damage areaggressive tumor growth.
consistent with the possibility that resistance to apopto-For tumors to progress and metastasize, they must
circumvent cellular responses to hyperproliferative sig- sis can produce genetically altered cells. One study
nals, hypoxia, nutrient factor deprivation, and altered shows that loss of p53 increases gene mutation fre-
cell adhesion. In addition, they must survive in a foreign quency following UV irradiation (Corbet et al., 1999),
environment and overcome or evade continual immune while another fails to demonstrate any significant effect
attack. Each hurdle provides further selective pressure (Griffiths et al., 1997). Both studies, however, show that
to disable apoptosis, such that by the time a tumor p53 loss increases the survival of cells following DNA
metastasizes, it is not surprising that it is highly resistant damage, and that these survivors harbor additional mu-
to physiologic and pharmacologic death-inducing sig- tations. Therefore, whether or not p53 affects the muta-
nals. This may explain, in part, why metastatic tumors tion rate directly, it clearly eliminates potentially mutated
are notoriously chemoresistant (Fidler, 1999). Indeed, cells. The possibility that cytotoxic drugs might actually
the observations that metastatic tumors are enriched mutagenize tumors that cannot be killed highlights the
for p53 mutations or overexpressed Bcl-2 support this necessity for a more rational approach for the future treat-
notion (Sierra et al., 2000). ment of cancer where the “cure matches the cause.”
What are the implications of these findings in terms
of future treatment of cancer with cytotoxic drugs? If
A More Rational Approach to Cancer Therapyinhibition of apoptosis is a necessary event for tumori-
Our understanding of the molecular links between tu-genesis and most chemotherapeutic drugs utilize intact
morigenesis, apoptosis, and drug resistance providesapoptotic pathways to induce cell death, it is little won-
the foundation for a new age of targeted cancer therapy.der that drug resistance is such a major clinical problem.
For example, information concerning key apoptotic pro-While this may greatly impede our chances of success-
teins, their regulation, and the manner in which they arefully treating tumors with conventional drugs and treat-
altered in tumor cells can be used for target selectionment regimes, our increasing knowledge of the molecu-
in designing new anticancer agents. Alternatively, alar links between tumorigenesis and apoptosis provides
“blueprint” of the proteins and pathways necessary fornew opportunities for a more tailored approach to che-
the cytotoxic action of a given drug, coupled with anmotherapy.
understanding of the molecular basis of drug resistance,
may provide the necessary information to tailor existingThe Potential Problem of Damage
therapies for individual tumors. Although substantiallywithout Cell Death
more information is needed, both strategies are alreadyMost conventional anticancer agents produce some
form of cellular damage and, indeed, directly or indi- being pursued with promising results.
Cell
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New Therapeutics such as hTERT can be reactivated by HDAC inhibitors,
which might contribute to cellular immortalization andAlthough conventional agents were not designed to in-
duce apoptosis, the fact that they do so indirectly dem- tumor progression (Takakura et al., 2001). Furthermore,
HDAC inhibitors might reactivate imprinted genes which,onstrates that apoptosis can be an effective mechanism
for eliminating tumor cells. In principle, agents that in- in other settings, are associated with several human
diseases, including cancer (Paulsen and Ferguson-Smith,duce apoptosis directly would overcome many of the
problems observed with existing drugs and, as a result, 2001). As the mechanisms of gene silencing at specific
loci are elucidated, it is possible that more specific strat-have great therapeutic potential. Such an approach
would have the following benefits. First, cell death is egies to reactivate discrete genes will be developed.
Antisense approaches to decrease expression of apreferable to cytostasis, since tumor cells are eliminated
and hence unable to contribute to tumor relapse. Sec- wide variety of antiapoptotic genes including Bcl-2, Ras,
X-IAP, and Mdm2 are in various stages of preclinicalond, apoptosis is preferable to necrosis, since it is a
particularly efficient mode of cell death that does not development (Cunningham et al., 2001; Jansen et al.,
2000; Sasaki et al., 2000; Tamm et al., 2001). Experi-produce inflammation and damage to the surrounding
normal tissue. Finally, agents that induce apoptosis di- ments in vitro and in vivo provide proof-of-principle that
such approaches may work. However, efficient delivery ofrectly should be less mutagenic than existing drugs and,
because they engage the program further downstream, the DNA to every tumor cell in vivo has not been perfected,
ensuring that such therapies are still some way fromless prone to resistance. However, such agents will be
just as toxic as conventional therapies unless they are being adapted for common clinical use. Specific small
molecule inhibitors of Bcl-2, which block Bcl-2 homo-designed to selectively kill tumor cells. Exploiting the
genetic and/or physiological differences between tumor and heterodimerization leading to cytochrome c release,
have now been developed (Wang et al., 2000). It is un-and normal cells may provide such an opportunity, and
establishes the basis for a truly targeted approach to clear whether these inhibitors will have specificity for
tumor cells or will be useful as “stand alone” therapies,cancer therapy.
Given that many of the apoptotic regulators altered however, as with CP-31398, the use of such molecules in
combination with other agents may have clinical benefit.in multidrug resistant tumors have been identified, one
new approach to therapy is to restore apoptotic poten- Other promising therapeutic targets include compo-
nents of the prosurvival signal transduction pathwaystial through genetic or pharmacological methods. The
direct relationship between p53, apoptosis, and drug involving Ras, Akt, or NF-B that contribute to intrinsic
or inducible drug resistance. For example, inactivationaction implies that restoring p53 activity in p53 null tu-
mors, or activating apoptotic pathways that are directly of NF-B by overexpression of I-B can restore sensitiv-
ity of tumor cells to chemotherapy (Baldwin, 2001). Sincedownstream of p53, would have clinical benefits. Rein-
troduction of wild-type p53 into p53 null tumors can I-B is normally kept at low levels by ubiquitin-mediated
proteolysis, one pharmacological approach to upregu-directly induce apoptosis and restore sensitivity to che-
motherapeutic drugs, while adenoviral gene transfer of late it is through proteosome inhibition, and there have
been exciting preclinical and early phase clinical trialBax activates apoptosis downstream of p53 and can
synergize with chemotherapy to promote tumor regres- results using the proteosome inhibitor PS-341. This agent
inhibits the degradation of I-B, thereby suppressingsion in vivo (Swisher et al., 1999; Tai et al., 1999). Small
molecules that reactivate mutant p53 provide a pharma- transcriptional activation by NF-B and sensitizing cells
to drug-induced apoptosis (Adams, 2001). PS-341 alsocological approach that is not prone to the limitations
of gene therapy. For example, CP-31398 promotes con- causes the induction of genes that inhibit cell cycle,
and suppression of genes that promote angiogenesis,formational stability of mutant p53 and restores the DNA
binding and transcriptional regulatory functions of mu- events that can all enhance the antitumor action of the
drug (Adams, 2001). The drug is remarkably nontoxic,tant protein (Foster et al., 1999). In preclinical studies,
CP-31398 can induce p53 transcriptional targets and has few adverse side effects and might be of great
benefit in combination therapies using reduced dosesinhibit the growth of p53 mutant cells in vitro and in
vivo. However, a concern with this approach is that most of existing chemotherapeutic drugs (Adams, 2001). In
addition, small molecule inhibitors of PI-3 kinase/Akttumors are usually hemizygous for the p53 mutant and
are genomically unstable. Therefore, a substantial num- (Ng et al., 2000), and farnysyltransferases, necessary
for the activity of Ras (Omer et al., 2000), can induceber of tumor cells may become p53 null by chance,
thereby producing resistance. apoptosis in vitro and in vivo, are relatively nontoxic to
normal cells, and mediate tumor regression in mice. TheIn certain circumstances, apoptotic pathways may be
inactivated in cancer by gene silencing rather than muta- usefulness of such agents in the clinic is currently under
investigation.tion. Silencing of INK4a/ARF, caspase-8, and Apaf-1 by
DNA methylation has been linked to drug resistance Rather than attempting to reactivate the intrinsic apo-
ptotic pathway, an alternative approach would be to(Robertson and Jones, 1998; Soengas et al., 2001; Teitz
et al., 2000). This provides the exciting possibility that engage a fundamentally different apoptotic program to
kill tumor cells. As discussed above, mutations in thetargeting the silencing mechanism may reactivate these
latent killers. In cultured cells, this can be achieved using death receptor pathway are not as frequent as those in
the intrinsic apoptotic pathway, such that this programdemethylating agents and/or histone deacetylase (HDAC)
inhibitors, and these agents are now in clinical trials might remain available to trigger an antitumor response.
Recently, a recombinant form of TRAIL has been tested(Marks et al., 2001). However, these agents lack specific-
ity, since normal gene expression can be controlled by as an antineoplastic agent. TRAIL induces the death
receptor pathway and is not affected by overexpressionsimilar mechanisms. Thus, epigenetically silenced genes
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of Bcl-2 or Bcl-XL (Walczak et al., 2000). TRAIL specifi- 5-FU does not induce apoptosis in p53 null colon carci-
cally targets tumor cells and is relatively nontoxic to noma cells (Bunz et al., 1999) and tumors expressing
untransformed cells, although the molecular events un- low levels of c-Myc or mutant p53 are relatively resistant
derlying this specificity are controversial. Importantly, to 5-FU treatment (Arango et al., 2001). Consistent with
TRAIL can synergize with subtoxic doses of conven- these studies, retrospective analyses of data from a
tional chemotherapeutic drugs to kill drug resistant tu- phase III clinical trial demonstrate that only those pa-
mor cells (Ashkenazi et al., 1999). These data highlight tients with colon carcinomas containing elevated c-Myc
the potential for combination therapies that simultane- and wild-type p53 respond significantly to 5-FU treat-
ously activate both the extrinsic and intrinsic apoptotic ment (Arango et al., 2001).
pathways. Although large-scale genotyping of tumors is still
Most conventional anticancer agents were selected years from the clinic, the use of drug-resistance markers
based on their ability to selectively kill tumor cells at to tailor cancer therapy has already been applied in a
clinically achievable doses. This tumor specificity has more simplistic manner. For example, leukemias that
been attributed to the increased proliferation rate of acquire drug resistance after an initial round of therapy
cancer cells, but this is almost certainly not a sufficient are often screened for the presence of P-gp. If P-gp
explanation. Instead, the answer may return to the no- is found to be expressed in the resistant tumors, new
tion that many cells possess mechanisms that couple therapeutic regimes using drugs that are not P-gp sub-
inappropriate cell division to apoptosis. While some de- strates, or combination therapies involving P-gp inhibi-
gree of apoptosis inhibition must accompany tumori- tors, are used. The recent findings that P-gp can both
genesis, it is clear that tumor cell survival reflects a fine efflux chemotherapeutic drugs and inhibit caspase acti-
balance between hyperproliferative, proapoptotic, and vation could lead to a further alteration to the criteria
antiapoptotic events. Thus, the addition of yet another for selecting drugs capable of killing P-gp expressing
apoptotic stimulus in the form of a chemotherapeutic tumors (Johnstone et al., 2000).
drug may tip the balance in favor of apoptosis, at least The use of markers to tailor therapy or predict treat-
in those cells containing a partially functional apoptotic ment response has been on a gene-by-gene basis, and
program. In contrast, normal cells, not “living on the the power of this approach will undoubtedly improve as
edge” may be less sensitive to these signaling alter- more information is obtained from each patient’s tumor.
ations. This property of malignant cells may therefore The time frame for the application of such rational ther-
be exploited to develop new, rationally designed thera- apy will depend largely on the ongoing classification of
peutic agents. the molecular mechanisms of drug action and on the ability
This concept has been put into practice by Kaelin and to rapidly profile the genetic makeup of a given tumor.
colleagues who designed novel drugs that target only Recent experiments using DNA microarray to classify tu-
those cells containing a specific tumorigenic lesion. Dis- mors based on gene expression patterns highlights the
ruption of the pRb tumor suppressor protein by direct advances in technology that should enable rapid, high-
mutation or altered expression of upstream regulators throughput tumor profiling (Sorlie et al., 2001).
such as cyclins, cyclin-dependent kinases (cdks), or cdk
inhibitors is commonly seen in human tumors (Harbour
Apoptosis and the Side Effects of Cancer Therapy
and Dean, 2000). pRb converts the E2F-1 transcription
The often debilitating side effects of chemotherapy are
factor from an activator to a repressor and, like c-Myc,
a major clinical problem. Although chemotherapeuticactive E2F-1 can promote both proliferation and apopto-
drugs would ideally specifically target only tumor cells,sis (Harbour and Dean, 2000). While pRb regulates E2F-1
normal hemopoietic and intestinal epithelial cells, andactivity during the G0/G1 phase of the cell cycle, cyclinA/ hair matrix keratinocytes are often susceptible to thecdk2 can bind and neutralize E2F-1 during S phase and
toxic effects of these agents (Komarova and Gudkov,mutation of the cyclinA/cdk2-binding motif in E2F-1 en-
2000). It now appears that drug toxicity is due, in part,hances its ability to induce apoptosis (Krek et al., 1995).
to apoptosis induced by p53. Hence, p53/ mice treatedTherefore, inhibition of cyclinA/cdk2 binding to E2F-1
with chemotherapeutic drugs or radiotherapy do notin cells containing inactive pRb would result in activation
suffer the same degree of damage in susceptible tis-of E2F-1 and induction of apoptosis. This hypothesis
sues, and can survive doses that are lethal for wild-typewas tested using soluble peptides that block the interac-
animals (Komarova and Gudkov, 2000). This apparentlytion of cyclinA/cdk2 with E2F-1. Apoptosis was readily
results from disruption of the intrinsic apoptotic pathwayinduced in tumor cells with inactivated pRb but not in
since ectopic expression of Bcl-2 in bone marrow cellsnormal cells, demonstrating the potential for rationally
achieves a similar effect (Domen et al., 1998). Impor-designed agents (Chen et al., 1999).
tantly, there is a direct correlation between p53 activa-Tailoring Cancer Therapy
tion and the sites of normal tissue toxicity (KomarovaA variation on the theme of rational drug design is the
and Gudkov, 2001). These studies highlight the reasonsidea of individualized therapy whereby the “cure circum-
underlying the general lack of success in developingvents the cause.” Theoretically, a more targeted ap-
drugs that can specifically kill target cells using an em-proach to chemotherapy might involve genotyping indi-
pirical approach. On one hand, p53 potentiates the ac-vidual tumors for their drug resistance profiles, and then
tion of most drugs but is functionally inactivated in mostemploying agents known to work effectively despite the
tumors. On the other hand, an intact p53 pathway inidentified antiapoptotic lesions. The potential of this ap-
normal cells contributes to their own destruction.proach is illustrated by a study demonstrating that tumor
In theory, it should be possible to reduce the “collat-cells with elevated levels of c-myc and wild-type p53
are selectively sensitive to 5-FU (Arango et al., 2001). eral damage” that gives rise to the side effects of chemo-
Cell
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